Leukocyte Immunoglobulin-Like Receptor B1 and its Interactions with Human Leukocyte Antigens

Interactions between Human Leukocyte Antigen (HLA) molecules and their cognate immunoreceptors are essential for regulating innate and adaptive immune cell functions. Leukocyte Immunoglobulin-like Receptors (LILRs) are key regulators of HLA-mediated immune responses, owing to their broad expression across immune cell populations and their ability to modulate both immune activation and tolerance. Among these, LILRB1-HLA interactions are increasingly recognised as important in transplantation, chronic infection and cancer therapies. Unlike other HLA-binding receptors, which recognise epitopes specific to HLA subsets, LILRB1 primarily engages the relatively conserved α3 and β2-microglobulin components of HLA molecules, supporting its role as a broad regulator of pan-HLA class I-mediated functions. Nonetheless, there have been conflicting findings regarding the breadth of LILRB1-HLA-I interactions. While direct affinity studies on a limited subset of HLA-I molecules have revealed no significant differences in LILRB1 binding, broader analyses using single-antigen bead arrays suggest underlying variability. Here, we show through a broad binding assay that, while LILRB1 is a broad HLA-I-binding receptor, it exhibits differential preferences across HLA-I allotypes. Molecular dynamics analyses of the HLA-I-LILRB1 interface suggest that HLA-α3 domain dynamism underlies these binding differences. We further determined the crystal structure of LILRB1 and used it to highlight intrinsic structural flexibility within its domains. Finally, these structural insights were leveraged to refine our understanding of the binding modalities of therapeutic monoclonal antibodies currently described. Together, our findings establish structural and mechanistic bases for differential HLA-I recognition by LILRB1 and provide insights into immunotherapeutic targeting of LILRB1.